AI assistant
FATE THERAPEUTICS INC — Proxy Solicitation & Information Statement 2017
Mar 22, 2017
34091_rns_2017-03-22_9b652834-a5ad-40cb-866b-ce03c44bf13d.zip
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
DEFA14A 1 d334013ddefa14a.htm DEFA14A DEFA14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
Fate Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. | |
|---|---|---|
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |
| (1) | Title of each class of securities to which transaction applies: | |
| (2) | Aggregate number of securities to which transaction applies: | |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing | |
| fee is calculated and state how it was determined): | ||
| (4) | Proposed maximum aggregate value of transaction: | |
| (5) | Total fee paid: | |
| ☐ | Fee paid previously with preliminary materials. | |
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement | |
| number, or the Form or Schedule and the date of its filing. | ||
| (1) | Amount Previously Paid: | |
| (2) | Form, Schedule or Registration Statement No.: | |
| (3) | Filing Party: | |
| (4) | Date Filed: |
Important Notice of Availability of Proxy Materials for the Stockholder Meeting of
FATE THERAPEUTICS, INC.
To Be Held On:
May 2, 2017 at 8:00 a.m. Pacific Time
3535 General Atomics Court, Suite 200, San Diego, California 92121
| COMPANY NUMBER |
|---|
| ACCOUNT NUMBER |
| CONTROL NUMBER |
| This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge
| to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 04/21/17. Please visit http://www.astproxyportal.com/ast/18615/, where the following materials are available for view: | ||
|---|---|---|
| Notice of Annual Meeting of Stockholders Proxy Statement Form of Electronic Proxy Card Annual Report on Form 10-K | ||
| TO REQUEST MATERIAL: | TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers) E-MAIL: [email protected] WEBSITE: | |
| http://www.amstock.com/proxyservices/requestmaterials.asp | ||
| TO VOTE: | ● | ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date. IN PERSON: You may vote your shares in person by attending the Annual Meeting. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. |
| 1. Election of two class I directors: NOMINEES: Robert S. Epstein, M.D., M.S. John D. Mendlein, Ph.D., J.D. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017. | | --- | --- | | 3. | To approve, under applicable Nasdaq listing rules, the issuance of 14,097,745 shares of the Companys common stock upon the conversion of 2,819,549 outstanding shares of the Companys Class A Convertible Preferred Stock. | | 4. | To approve an amendment and restatement of the Companys 2013 Stock Option and Incentive Plan and to approve the material terms for payment of performance-based compensation. | | 5. | To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. | | In her discretion, the proxy is authorized to vote upon such other business as may properly come before the Annual Meeting. | | | THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF DIRECTORS AND FOR PROPOSALS 2, 3 AND 4. | | | Please note that you cannot use this notice to vote by mail. | |